Trial Profile
A Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2, Dose-finding Study With ACT-132577 in Subjects With Essential Hypertension (Grade 1 and 2).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Aprocitentan (Primary) ; Lisinopril
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 23 May 2022 Results published in the Idorsia Media Release.
- 31 Aug 2019 Results published in the Idorsia Pharmaceuticals Media Release
- 04 Dec 2017 According to a Idorsia media release, the study was completed in May 2017.